Platform Heritage

ONETest™ Respiratory & Surveillance Programs.

At Fusion Genomics, our legacy portfolio showcases how QuantumProbes™ targeted metagenomics supported respiratory-virus detection, SARS-CoV-2 genome sequencing, environmental surveillance, and One Health applications.

These programs helped establish the platform foundation for today’s ONETest™ PathoGenome and FusionCloud™ Actionable Intelligence strategy.

764

Toronto clinical respiratory specimens evaluated against conventional testing.

70

UF SARS-CoV-2-positive respiratory samples processed for genome sequencing.

345

Wetland and farm sediment samples analyzed for avian influenza surveillance.

10+

Respiratory-virus groups represented in the legacy viral assay portfolio.

Historical studies and materials are summarized for platform context. Current product availability and use remain subject to applicable laboratory validation and regulatory requirements.

Legacy Technology Foundation

QuantumProbes™ before PathoGenome.

The legacy respiratory and surveillance assays demonstrated a central Fusion principle: targeted capture can enrich informative microbial signal while retaining sequence-level context for typing, lineage assignment, and surveillance.

01

Target enrichment

Probe-based capture focused sequencing on informative viral loci and reduced dependence on deep whole-metagenome sequencing.

02

Broad viral scope

Legacy panels covered SARS-CoV-2, seasonal coronaviruses, influenza A/B, RSV, hMPV, parainfluenza, enterovirus/rhinovirus, parechovirus, adenovirus, and bocavirus.

03

Sequence characterization

The platform supported subtype, lineage, phylogenetic, and abundance-informed analysis rather than limiting output to a binary detection call.

04

Difficult samples

Clinical swabs, endotracheal aspirates, wetland sediment, farm waterbody sediment, wastewater, and wildlife-related samples informed the platform’s evolution.

Program Portfolio

ONETest™ platform across clinical, environmental, and One Health use cases.

The legacy ONETest™ respiratory-virus portfolio was applied across four complementary verticals, each demonstrating a different value of targeted metagenomics.

Clinical Respiratory Viruses

Toronto hospital evaluation

Clinical respiratory specimens from Toronto hospitals were compared against conventional respiratory-virus assays to evaluate ONETest™ detection and agreement.

95%+
specimens
764
specificity range
SARS-CoV-2 Genomics

UF target-capture sequencing

ONETest™ Coronaviruses Plus was applied to SARS-CoV-2-positive respiratory samples and compared with ARTIC amplicon sequencing.

64%
near-complete genomes
14
lineages detected
Environmental Surveillance

Avian flu in wetland sediment

Sediment-based targeted resequencing was used to detect and characterize avian influenza virus across wetland and farm-associated samples.

13
HA subtypes
9
NA subtypes
Wastewater & Wildlife

Population-level surveillance

Airport wastewater and wildlife-oriented studies extended the platform into surveillance settings where population-level viral signals can inform public-health awareness.

YYZ
airport wastewater
One
Health lens
Clinical Evaluation

Respiratory-virus detection in Toronto clinical specimens.

The Toronto clinical study evaluated ONETest™ as a target-capture next-generation sequencing platform for detecting and identifying medically important respiratory viruses in symptomatic and asymptomatic cohorts.

Across pathogens tested, ONETest™ demonstrated high specificity and strong agreement with conventional respiratory-virus assays, while providing sequence-based evidence, breadth-of-coverage information, and normalized abundance measures.

537

symptomatic-patient specimens

227

asymptomatic outpatient specimens

75–100%

sensitivity range

95–100%

specificity range

Interpretation: This legacy clinical dataset provides historical evidence that QuantumProbes™-enabled targeted metagenomics could detect multiple respiratory-virus groups in a single sequencing workflow while generating sequence-level data for downstream characterization.
SARS-CoV-2 & Wastewater

Target capture for viral genome recovery and surveillance.

During the COVID-19 era, ONETest™ Coronaviruses Plus extended the legacy respiratory-virus platform into SARS-CoV-2 genome sequencing and wastewater surveillance.

UF Health Study

SARS-CoV-2 genome sequencing from respiratory samples

In a published UF Health study, ONETest™ generated complete or near-complete SARS-CoV-2 genomes in 45 of 70 PCR-positive respiratory samples and showed fewer coverage-loss regions than ARTIC in key comparisons.

45/70
ONETest genomes
25/48
ARTIC genomes
14
lineages detected
Airport Wastewater

A population-level early-warning use case

Fusion’s Toronto airport wastewater work applied ONETest™-based target enrichment and FusionCloud™ analysis to respiratory pathogens and SARS-CoV-2 variant patterns across airport locations and collection dates.

100%
SARS-CoV-2 genome target
10+
viral groups
ML
analysis pipeline
One Health Surveillance

Avian influenza detection from wetland sediment.

In collaboration-linked programs involving BC public-health, agriculture, and academic partners, ONETest™-based targeted resequencing was applied to wetland and farm sediment samples collected during the 2014–2015 avian influenza outbreak in British Columbia.

These studies demonstrated the feasibility of sediment as a pooled environmental substrate for detecting and characterizing avian influenza virus diversity.

20.6%

AIV-positive sediment samples

Journal of Wildlife Diseases study: AIV was identified in 71 of 345 wetland and farm sediment samples.

22.9%

Targeted resequencing positives

Frontiers study: enrichment-based targeted resequencing identified AIV sequences in 79 of 345 RNA extracts.

13 HA

Subtype breadth

Multiple hemagglutinin subtypes were detected, including H5 and other environmentally relevant AIV signals.

8 + 8

Polymicrobial viral ecology

As many as eight HA and eight NA subtypes were detected in a single sediment sample.

Evidence Timeline

A platform history that preceded today’s ONETest™ PathoGenome.

The legacy portfolio created a technical and operational foundation for later hospital-focused targeted metagenomics programs.

2018–2019: Avian influenza pilot

BC Ministry of Agriculture and BCCDC-linked pilot work explored wetland sediment as a surveillance substrate for avian influenza genomic analysis.

2019: ERVINGS respiratory-virus assessment

Targeted enrichment was assessed for seasonal respiratory-pathogen surveillance, including semi-quantitative FPKM and coverage relationships with Ct values.

2020: Wetland sediment AIV studies

Published studies showed targeted resequencing could detect and characterize avian influenza diversity from complex sediment matrices.

2021: SARS-CoV-2 target-capture publication

ONETest™ Coronaviruses Plus was published as a target-capture approach for SARS-CoV-2 genome sequencing from UF respiratory samples.

Today: PathoGenome and FusionCloud™

The same targeted-metagenomic foundation now supports ONETest™ PathoGenome, focused on hospital-deployable infectious-disease workflows and Actionable Intelligence.

Bridge to Current Platform

From upper-respiratory surveillance to critical-care metagenomics.

The legacy ONETest™ respiratory-virus programs showed that targeted capture could recover actionable microbial sequence information from challenging sample types. ONETest™ PathoGenome extends this principle into lower-respiratory and critical-care infection workflows, integrating broader pathogen coverage, automation, and FusionCloud™ Actionable Intelligence.

Legacy Resources

Publications, posters, and technical sheets.

Selected legacy materials can be linked here as public resources or retained as internal supporting documentation.

Legacy Program Notice

Historical research and development materials.

The ONETest™ respiratory-virus and environmental-surveillance programs described on this page reflect historical research, development, and collaborative studies conducted by Fusion Genomics and partners. These legacy programs are presented for platform-history and evidence-context purposes.

These materials are not intended to represent currently marketed diagnostic products. ONETest™ reagents and software are supplied for research use only unless independently validated and used by an appropriately accredited laboratory under its applicable regulatory, accreditation, and quality framework.

Platform Continuity

The same core principle now powers ONETest™ PathoGenome.

Targeted metagenomics, automation, and FusionCloud™ interpretation have evolved from legacy respiratory-virus surveillance into hospital-ready workflows for critical-care infection diagnosis.